May 1, 2017

IntegriChain Launches Specialty Pharmaceutical Analytics and Enriched Data Platform to Optimize Patient Access and Patient Experience

Specialty Brands Now Have the Capabilities to Move Beyond Baseline Metric Reporting and Achieve Actionable Patient Data Insights

Philadelphia, PA, May 1, 2017 – IntegriChain, a leading healthcare technology company delivering enriched data and analytics for distribution, patient access, and market access, today announced the launch of Specialty Analytics, a cloud-based, actionable specialty patient-level insights platform. Specialty Analytics empowers market access and national account teams to optimize investments in specialty services that will help patients initiate and remain on life-changing therapies. Specialty Analytics launches against the backdrop of a dramatic market shift away from traditional pharmaceuticals to specialty products that require a higher degree of patient engagement to achieve successful outcomes.

“Estimates show that spending on specialty drugs is set to outpace spending on traditional pharmaceutical products at least threefold in the next five years,” said Brandon Underwood, Product Marketing Manager. “Traditional analytics solutions are falling short as brands search for more predictive, data-driven methods to improve specialty product patient access.”

“Specialty Analytics improves the actionability of specialty pharmacy data, allowing brands and their account and access teams to proactively identify and address the greatest challenges that can impact the patient access, and ultimately deliver a differentiated patient experience,” said Sunay Shah, Executive Director, Product Management. “This platform enables brand teams to make the leap from manually digging through data in lagging trend reports to a set of readily available analytics that explains the why behind those trends and expedites the time it takes to arrive at actionable insights.”

About IntegriChain Specialty Analytics

By accessing enriched data insights, network benchmarks, and data confidence alerting available in the Specialty Analytics platform, brand teams can begin to realize and fine-tune the substantial investments they are making in this area. These investments include patient services delivered through contracted specialty pharmacies and hubs, access and reimbursement teams, and financial assistance programs.

IntegriChain Specialty Analytics addresses the major challenges currently keeping specialty stakeholders from progressing to a more mature, actionable analytics model.

  • Inconsistent Patient-Level Data – Diagnostic analytics identify where and why specialty pharmacies, brands, and payers are underperforming
  • Small Patient Cohorts – Stakeholders relying on specialty data to inform day-to-day decisions receive data confidence alerts when values are missing or outliers could undermine actions
  • Missing Market Context – Network benchmarking provides market basket comparative metrics for broader context and the ability to diagnose brand, payer, provider, and/or category-wide issues
  • Fragmented Platforms – Integration of distribution and retail pharmacy data provides true visibility and analytics from factory shipment through the patient access

About IntegriChain
IntegriChain is a rapidly growing healthcare technology company, offering the leading cloud for enriched data and analytics to optimize distribution, patient access, and market access for life sciences managed markets teams. Pharmaceutical, biopharm/specialty pharma, generics, and medtech suppliers leverage insights from IntegriChain’s unmatched factory-to-patient visibility to maximize patient access and to address critical risks throughout the patient access and product life cycle. IntegriChain delivers the enriched data and analytics foundation for more efficient and service-oriented channel models for mature product categories as well as for innovative products that must balance significant therapeutic benefit with out-of-pocket costs and benefit hurdles. Today IntegriChain is the trusted partner for all top-10 bio/pharmaceutical companies, 17 of the top-20 life science companies, and more than 50 other suppliers, totaling more than $250 billion in annual US commerce. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. For more information, visit and our blog, and follow us on Twitter @IntegriChain and LinkedIn.

IntegriChain is a registered trademark of IntegriChain Incorporated. All other trademarks are property of their respective owners.

Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 |

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article